The Beatrice Hunter Cancer Research Institute logo
  • Chungen Pan, PhD


Dr. Roy Duncan

Program of Study:

Postdoctoral Fellow, Microbiology and Immunology

Project Title:

The functions of Synpo2 on Rho signaling pathway and actin assembly

Scholarships and/or Awards:

  • Cancer Research Training Program (CRTP) Traineeship Award 2014
  • 2010.07 ‐ 2011.07 "One‐Hundred‐Talent” scholar from Sun Yat‐Sen University (250,000RMB)
  • 2007.09 ‐ 2009.09 A two‐years scholarship from the China Scholarship Council
  • 2006.06 Academic Excellence Award from Peking University

Career Aspirations:

Chungen has been motivated and inspired to enhance her professional knowledge and skills to achieve advancement in cancer research, particularly understanding the pathogenesis of cancers, with a long-term goal to develop anticancer therapeutics.


Dalhousie University


Lu, L., Wei, M., Chen, Y., Xiong, W.,Yu, F.,  Qi, Z., Jiang, S.* and Pan, C.* (2013) F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. Microbes Infect. 15(13):887-94 (*Corresponding author)

Wang, X., Zhou, S., Chen, Y., Wei, M., Xiong, W., Yi, X., Jiang, S. and Pan, C* (2013). Multiple amino acid mutations in viral RNA polymerase may synergistically enhance the transmissibility and/or virulence of the 2009 pandemic influenza (H1N1) virus. Acta virologica 57: 35-40 (*Corresponding author)

Lu, L., Pan, C., Li, Y., Lu, H., He, W. and Jiang, S. (2012). A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology. 9:104

Wang, X., Xiong, W., Ma, X., Wei M., Chen, Y., Lu, L., Debnath, AK, Jiang, S. and Pan, C*. (2012). The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for vial fusion and entry. PLoS One. Sep 7(9): e44874 (*Corresponding author).
Lu, L., Tong, P., Yu, X., Pan, C., Zou, P., Chen, Y, and Jiang, S. (2012). HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Biochim Biophys Acta. Jul 31;1818(12):2950-2957.

Ma, X., Zhou, S., Wei, M., Li, J., Chen, Y., Wang, X., Jiang, S. and Pan, C*. (2012). Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus - xenotropic murine leukemia virus-related virus (XMRV). Virus Genes. 45(2):218-224 (*Corresponding author).

Pan, C., * Ma, X. and Jiang, S. (2012). What can academia learn from XMRV studies? Nature Reviews Urology. 9(3):174 (*Corresponding author).

Cai, L.,* Pan, C.,* Xu, L., Shui, Y., Liu, K. and Jiang, S. (2012). Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination. The FASEB Journal. 26(3):1018-26 (*Co-first author).

Pan, C.,* Cai, L.,* Lu, H., Lu, L., Jiang, S. (2011). A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 with high potency and stability. J Biol Chem. 286 (32):28425-34 (*Co-first author).

Liu, S., Li, R., Zhang, R., Chan, C.C.S., Xi, B., Xia, C., Poon, V.K.M., Zhou, J., Chen, M., Münch, J., Kirchhoff, F., Pleschka, S., Haarmann, T., Dietrich, U., Pan, C., Du, L., Jiang, S., Zheng, B. (2011). CL-385319 inhibits H5N1 avian influenza virus infection by blocking viral entry. Eur. J. Pharmacol. 660, 460-467.

Site by: Spectacle Group